THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY

被引：0
|
作者：
Corren, Jonathan
Ambrose, Christopher
Salapa, Kinga
Parnes, Jane
Colice, Gene
机构：
来源：
CHEST | 2020年 / 158卷 / 04期
关键词：
D O I：
10.1016/j.chest.2020.08.070
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：30A / 31A
页数：2
相关论文
共 50 条
  • [1] EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA, ACCORDING TO BASELINE BODY MASS INDEX: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Ambrose, C. S.
    Colice, G.
    Salapa, K.
    Parnes, J. R.
    Corren, J.
    THORAX, 2021, 76 : A83 - A83
  • [2] Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study
    Ambrose, Chris
    Colice, Gene
    Salapa, Kinga
    Parnes, Jane
    Corren, Jonathan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB25 - AB25
  • [3] Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study
    Corren, J.
    Garcia Gil, E.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] The Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma According to Baseline Serum IL-5 and IL-13 Levels: Results from the Phase 2b PATHWAY Study
    Corren, J.
    Ambrose, C.
    Salapa, K.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [6] Seasonal variability of exacerbations in patients with severe, uncontrolled asthma and clinical benefits of tezepelumab: Results from the PATHWAY phase 2b study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    ALLERGY, 2020, 75 : 17 - 18
  • [7] Inhaled corticosteroid dose reduction with tezepelumab in patients with severe, uncontrolled asthma over 2 years
    Stolz, Daiana
    Lugogo, Njira
    Lawson, Kaitlyn
    Colice, Gene
    Ponnarambil, Sandhia
    Caveney, Scott
    Chandarana, Shradha
    Cook, Bill
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [8] Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Karpefors, Martin
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 1 - 10
  • [9] Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from
    Wechsler, Michael E.
    Stolz, Daiana
    Lugogo, Njira L.
    Caveney, Scott
    Almqvist, Gun
    Bednarczyk, Artur
    Kotalik, Ales
    Chandarana, Shradha
    Ambrose, Christopher S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (11):
  • [10] Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, C.
    Corren, J.
    Saapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345